World leaders in oral ketamine research
Over the past ten years, Brain & Mind Hub's Dr. Jim Lagopoulos and his team have become world leaders in oral ketamine research and how it can help treat mental health conditions.
The work of Dr. Jim Lagopoulos and his team has focused on people struggling with treatment-resistant depression, PTSD, and suicidality, making important discoveries that have expanded global knowledge in this field.
More importantly, they have turned their research into real-world treatments, bringing meaningful change to the community through their work at Brain & Mind Hub.
The team conducted the first-ever trial using low-dose oral ketamine for PTSD, and the results confirmed that it is a safe and effective treatment option. The study found that 73% of participants experienced significant relief from PTSD symptoms immediately after treatment, with 59% still benefiting a month later.
Beyond its impact on symptoms, the research also uncovered new biological insights into how ketamine works. The team discovered changes in blood biomarkers, including BDNF and VEGF-A, which play a key role in brain cell growth and repair. These findings help explain how ketamine supports recovery in people with PTSD.
In another groundbreaking study, the team investigated how oral ketamine could help people struggling with chronic suicidal thoughts. Their research showed that oral ketamine provided rapid relief, significantly reducing suicidal ideation. By the end of the six-week trial, 69% of participants experienced clinical improvement, with 50% maintaining these benefits over the long term.
In a follow-up study, the team discovered that oral ketamine was linked to an increase in grey matter volume in areas of the brain associated with depression and suicidality. These brain changes suggest that ketamine supports neuroplasticity, meaning it may help repair and strengthen brain connections, potentially reversing the brain shrinkage often seen in people with chronic mental health conditions.
The results of these studies were published in international scientific journals, confirming that ketamine not only helps reduce symptoms of depression and suicidality but also creates positive changes in the brain that may support long-term recovery.
The research, led by Dr. Lagopoulos and his colleagues at Brain & Mind Hub highlights the huge potential of oral ketamine as a game-changing treatment for PTSD, depression, and chronic suicidality. Their work shows that ketamine provides rapid relief from symptoms while also helping the brain heal and rebuild, offering hope for lasting recovery.
Dr. Lagopoulos has been a driving force in turning cutting-edge research into real-world mental health solutions. As CEO of Brain & Mind Hub, he has been committed to making innovative treatments more accessible, using data-driven approaches to improve mental health care. Likewise, Dr. Adem Can and Dr. Megan Dutton have played key roles in conducting research that directly benefits patients, ensuring that their discoveries lead to better treatment options.
Over the past six years, their collective efforts have made them global leaders in ketamine research. Their groundbreaking studies have not only deepened scientific understanding but also transformed the way PTSD, depression, and suicidality are treated worldwide.
By closing the gap between research and real-world care, the Brain & Mind Hub team has set a new standard in mental health treatment, bringing hope to countless individuals while making major contributions to the scientific understanding of stress-related mental health conditions.